Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2109-2117

  Van Vaerenbergh, Kristien ^a   Van Laethem, Kristel ^a   Albert, Jan ^b,k   Boucher, Charles A B ^c   Clotet, Bonaventura ^d   Floridia, Marco ^e   Gerstoft, Jan ^f   Hejdeman, Bo ^g   Nielsen, Claus ^f   Pannecouque, Christophe ^a   Perrin, Luc ^h   Pirillo, Maria F ^e   Ruiz, Lidia ^d   Schmit, Jean Claude ^l   Schneider, François ^l   Schoolmeester, Anne ⁱ   Schuurman, Rob ^c   Stellbrink, Hans J ^j   Stuyver, Lieven ⁱ   Van Lunzen, Jan ^j   Van Remoortel, Barbara ^a   Van Wijngaerden, Eric ^a   Vella, Stefano ^e   Witvrouw, Myriam ^a   Yerly, Sabine ^h   De Clercq, Erik ^a   Desmyter, Jan ^a   Vandamme, Anne Mieke ^a   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d IrsiCaixa Foundation   (Spain)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f STATENS SERUM INSTITUT   (Denmark)

^g STOCKHOLM SÖDER HOSPITAL   (Sweden)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ INNOGENETICS   (Belgium)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l Huddinge University Hospital ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BACTERIAL MUTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; EUROPE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

EID: 0033914679     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2109-2117.2000     Document Type: Article

References (20)

1. de Jong, J. J., J. Goudsmit, V. V. Lukashov, M. E. Hillebrand, E. Baan, R. Huismans, S. A. Danner, J. H. ten Veen, F. de Wolf, and S. Jurriaans. 1999. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 13:75-80.
2. Gómez-Cano, M., A. Rubio, T. Puig, M. Perez-Olmeda, L. Ruiz, V. Soriano, J. A. Pineda, L. Zamora, N. Xaus, B. Clotet, and M. Leal. 1998. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 12:1015-1020.
3. Horwitz, J. P., J. Chua, and M. Noel. 1964. Nucleosides. V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranoxyl) thymine. J. Org. Chem. 29:2076-2078.
4. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
5. Kavlick, M. F., K. Wyvill, R. Yarchoan, and H. Mitsuya. 1998. Emergence of multidideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J. Infect. Dis. 98:1506-1513.
6. Kosalaraksa, P., M. F. Kavlick, V. Maroun, R. Le, and H. Mitsuya. 1999. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J. Virol. 73:5356-5363.
7. Larder, B., S. Bloor, D. Kemp, K. Hertogs, R. L. Desmet, V. Miller, M. Sturmer, S. Staszweski, J. Ren, D. K. Stammers, D. I. Stuart, and R. Pauwels. 1999. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 43:1961-1967.
8. Najera, I., D. D. Richman, I. Olivares, J. M. Rojas, M. A. Peinado, M. Perucho, R. Najera, and C. Lopez-Galindez. 1994. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retrovir. 10:1479-1488.
9. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
10. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
11. Schinazi, R. F., B. Larder, and J. W. Mellors. 1999. Mutations in retroviral genes associated with drug resistance: 1999-2000 update. Int. Antivir. News 7:46-69.
12. Schmit, J.-C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1996. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174:962-968.
13. Schmit, J.-C., K. Van Laethem, L. Ruiz, P. Hermans, S. Sprecher, A. Sonnerborg, M. Leal, T. Harrer, B. Clotet, V. Arendt, E. Lissen, M. Witvrouw, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1998. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 12:2007-2015.
14. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
15. Stuyver, L., A. Wyseur, A. Rombout, J. Louwagie, T. Scarcez, C. Verhofstede, D. Rimland, R. F. Schinazi, and R. Rossau. 1997. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:284-291.
16. Vandamme, A.-M., K. Van Laethem, and E. De Clercq. 1999. Managing resistance to anti-HIV drugs. An important consideration for effective disease management. Drugs 57:337-361.
17. Vandamme, A.-M., K. Van Vaerenbergh, and E. De Clercq. 1998. Anti-human immunodeficiency virus drug combination strategies. Antivir. Chem. Chemother. 9:187-203.
18. Vandamme, A.-M., M. Witvrouw, C. Pannecouque, J. Balzarini, K. Van Laethem, J.-C. Schmit, J. Desmyter, and E. De Clercq. 1999. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In D. Kinchington and R. F. Schinazi (ed.), Methods in cellular and molecular medicine: antiviral chemotherapy. The Humana Press Inc., Totowa, N.J.
19. Van Laethem, K., K. Van Vaerenbergh, J.-C. Schmit, S. Sprecher, P. Hermans, V. De Vroey, R. Schuurman, T. Harrer, M. Witvrouw, E. Van Wijngaerden, L. Stuyver, M. Van Ranst, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1999. Phenotypic assays and sequencing are less sensitive than point mutation assays for the detection of resistance in mixed HIV-1 genotypic populations. J. Acquir. Immune Defic. Syndr. 22:107-118.
20. Winters, M. A., K. L. Coolley, Y. A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, and T. C. Merigan. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 102: 1769-1775.